Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Assets of $1.2 billion for Q4 2025, up 17.38% on a QoQ basis from $991.7 million in Q4 2024, and up 17.38% year-over-year from $991.7 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Assets data on file, last reported at $1.2 billion in Q4 2025.

  • In Q4 2025, Assets rose 17.38% year-over-year to $1.2 billion; the TTM figure through Dec 2024 stood at $991.7 million (up 275.25% YoY), while the FY2025 annual figure was $1.2 billion, up 17.38% from the prior year.
  • Assets climbed to $1.2 billion in Q4 2025, from $991.7 million in the prior quarter.
  • Across five years, Assets topped out at $1.2 billion in Q4 2025 and bottomed at $264.3 million in Q4 2023.
  • A 3-year average of $806.6 million and a median of $991.7 million in 2024 frame the typical range for Assets.
  • Annual changes were most pronounced in 2024 — Assets jumped 275.25% — and 2025, when it gained 17.38%.
  • Year by year, Assets stood at $264.3 million in 2023, then jumped by 275.25% to $991.7 million in 2024, then rose by 17.38% to $1.2 billion in 2025.
  • The last three Assets figures came in at $1.2 billion (Q4 2025), $991.7 million (Q4 2024), and $264.3 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 1.16 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.16 Bn
Dec 31, 2024 991.68 Mn
Dec 31, 2023 264.27 Mn